Yonghua Jing

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. doi request reprint Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression
    Yonghua Jing
    Bristol Myers Squibb, Plainsboro, New Jersey, USA
    Clin Ther 33:1246-57. 2011
  2. doi request reprint Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010)
    Yonghua Jing
    Bristol Myers Squibb, Plainsboro, Connecticut, USA
    Int Clin Psychopharmacol 28:87-90. 2013
  3. pmc One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis
    Edward Kim
    Bristol Myers Squibb, Plainsboro, NJ, USA
    BMC Psychiatry 11:6. 2011
  4. doi request reprint Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis
    Edward Kim
    Bristol Myers Squibb, Plainsboro, New Jersey 08536, USA
    Clin Ther 31:836-48. 2009
  5. doi request reprint A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level
    Zhenchao Guo
    Bristol Myers Squibb, Wallingford, CT 06492, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:1326-32. 2011
  6. doi request reprint Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder
    Yonghua Jing
    Bristol Myers Squibb Company, Plainsboro, NJ, USA
    J Med Econ 14:777-86. 2011
  7. ncbi request reprint Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone
    Yonghua Jing
    Bristol Myers Squibb, Plainsboro, NJ 08536, USA
    J Med Econ 12:104-13. 2009
  8. doi request reprint Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia
    Michael S Broder
    Bristol Myers Squibb Company, Plaisboro, NJ, USA
    J Med Econ 15:105-11. 2012

Detail Information

Publications8

  1. doi request reprint Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression
    Yonghua Jing
    Bristol Myers Squibb, Plainsboro, New Jersey, USA
    Clin Ther 33:1246-57. 2011
    ..To compare health care utilization and expenditures in patients with depression whose initial antidepressant (AD) treatment was augmented with a second-generation antipsychotic...
  2. doi request reprint Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010)
    Yonghua Jing
    Bristol Myers Squibb, Plainsboro, Connecticut, USA
    Int Clin Psychopharmacol 28:87-90. 2013
    ..Aripiprazole was mostly prescribed at therapeutic doses (pre-FDA and post-FDA approval), although the mean dose decreased significantly over time...
  3. pmc One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis
    Edward Kim
    Bristol Myers Squibb, Plainsboro, NJ, USA
    BMC Psychiatry 11:6. 2011
    ..This study compared 1-year risk of psychiatric hospitalization and treatment costs in commercially insured patients with bipolar disorder, treated with aripiprazole, ziprasidone, olanzapine, quetiapine or risperidone...
  4. doi request reprint Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis
    Edward Kim
    Bristol Myers Squibb, Plainsboro, New Jersey 08536, USA
    Clin Ther 31:836-48. 2009
    ....
  5. doi request reprint A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level
    Zhenchao Guo
    Bristol Myers Squibb, Wallingford, CT 06492, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:1326-32. 2011
    ..One of the limitations of a claims data analysis is the lack of information on potential confounders such as ethnicity and weight...
  6. doi request reprint Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder
    Yonghua Jing
    Bristol Myers Squibb Company, Plainsboro, NJ, USA
    J Med Econ 14:777-86. 2011
    ..To compare second-generation antipsychotics on time to and cost of psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder...
  7. ncbi request reprint Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone
    Yonghua Jing
    Bristol Myers Squibb, Plainsboro, NJ 08536, USA
    J Med Econ 12:104-13. 2009
    ..This study compared healthcare costs in patients treated with a mood stabilizer and adjunctive aripiprazole versus adjunctive olanzapine, quetiapine, risperidone or ziprasidone...
  8. doi request reprint Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia
    Michael S Broder
    Bristol Myers Squibb Company, Plaisboro, NJ, USA
    J Med Econ 15:105-11. 2012
    ..To examine the effect of antipsychotic medication half-life on the risk of psychiatric hospital admission and emergency department (ED) visits among adults with schizophrenia...